| Literature DB >> 26279360 |
Charles E Egwuagu1, Cheng-Rong Yu2, Lin Sun2, Renxi Wang3.
Abstract
Cytokines coordinate the activities of innate and adaptive immune systems and the Interleukin 12 (IL-12) family of cytokines has emerged as critical regulators of immunity in infectious and autoimmune diseases. While some members (IL-12 and IL-23) are associated with the pathogenesis of chronic inflammatory diseases, others (IL-27 and IL-35) mitigate autoimmune diseases. Unlike IL-12, IL-23 and IL-27 that are produced mainly by antigen presenting cells, IL-35 is predominantly secreted by regulatory B (i35-Bregs) and T (iTR35) cells. The discovery that IL-35 can induce the conversion or expansion of lymphocytes to regulatory B and T cells has considerable implications for therapeutic use of autologous regulatory B and T cells in human diseases. Although our current understanding of the immunobiology of IL-35 or its subunits (p35 and Ebi3) is still rudimentary, our goal in this review is to summarize what we know about this enigmatic cytokine and its potential clinical use, particularly in the treatment of CNS autoimmune diseases. Published by Elsevier Ltd.Entities:
Keywords: Adoptive B cell therapy; Autoimmune diseases; Breg; Cytokine therapy; IL-12 family cytokines; Interleukin 35; Regulatory B cells; i35-Breg; iTR35
Mesh:
Substances:
Year: 2015 PMID: 26279360 PMCID: PMC4581966 DOI: 10.1016/j.cytogfr.2015.07.013
Source DB: PubMed Journal: Cytokine Growth Factor Rev ISSN: 1359-6101 Impact factor: 7.638